This review discusses the challenges of managing cardiorenal syndrome with conventional therapies and highlights novel promising treatments.
Novel cardiorenal syndrome therapies remain investigational; randomized trials are needed before clinical adoption.
In heart failure, as the heart gets worse, often so do the kidneys, complicating the treatment of heart failure and worsening the prognosis. This article addresses challenges in the use of diuretics, angiotensin-converting enzyme (ACE) inhibitors, and other therapies in the cardiorenal syndrome, as well as novel therapies that hold promise, such as arginine vasopressin antagonists, adenosine A1 receptor antagonists, and ultrafiltration.
No takes yet. Share an insight, caveat, or question.
Geisberg et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: